NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
Dr Ouvry brings 20 years of international medicinal chemistry experience gained at Evotec, Galderma, AstraZeneca and SCYNEXIS.
- Dr Ouvry brings 20 years of international medicinal chemistry experience gained at Evotec, Galderma, AstraZeneca and SCYNEXIS.
- NRG Therapeutics’ co-founder and CEO Dr Neil Miller said, “We are expanding following our £16m series A financing and I am delighted to welcome Gilles to our team.
- There is now a substantial body of evidence demonstrating mitochondrial failure or dysfunction is common across many degenerative diseases.
- Gilles Ouvry Ph.D., VP of Chemistry at NRG Therapeutics said, “I have been impressed by the potential of NRG’s small molecules and am excited to be working with the team to move the programs forward.